Pre-Made Insulin Efsitora Alfa Biosimilar, Fusion Protein targeting INSR fused with human IGHG2 Fc (Fragment constant): Recombinant therapeutic protein targeting CD220/HHF5 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Insulin Efsitora Alfa is a human insulin B-chain fused via a G2SG4 peptide linker to human insulin A-chain variant and a peptide linker to a human immunoglobulin G2 Fc fragment. It is used as an antidiabetic drug.